Fusen Pharmaceutical Co., Ltd. (HK:1652) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Fusen Pharmaceutical Co., Ltd. has announced the passing of its Chairman, Mr. Cao Changcheng, and the appointment of his son, Mr. Cao Zhiming, as the new Chairman. The company has assured investors that this transition will not affect its business operations. Mr. Zhiming, with over 12 years of experience in securities and corporate finance, holds a significant stake in the company and is set to continue the strategic direction established by the Board.
For further insights into HK:1652 stock, check out TipRanks’ Stock Analysis page.